PM Group today announced a major project win for its new Shanghai office to provide Site Master Planning and Engineering Design services for BeiGene’s Biologics Manufacturing Facility, located in Guangzhou, Guangdong province, China.
The BeiGene facility is a US$330 million direct investment to establish a state-of-the-art commercial-scale biologics manufacturing plant and to provide funding for research and development of biologic drug candidates in China.
“We are very pleased to be partnering with one of China’s leading Pharma companies where we will provide essential expertise and experience delivering complex projects in the burgeoning biologics sector,” said Dave Murphy, CEO, PM Group.
BeiGene is a globally focused, clinical-stage biopharmaceutical company developing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer. PM Group is an international project delivery company headquartered in Ireland, with offices operating across Europe, the USA and Asia. For this project, PM Group will work in partnership with EDRI, a local design institute, to deliver the engineering design and facility integration.
"The launch of the BeiGene project highlights the strong growth of investment in the biologics sector in China. This is a fast track project with a multi-disciplinary project team from BeiGene and PM Group as well as other equipment and service providers. We are looking forward to delivering this project, which will be technically challenging but is a good fit with our capabilities," said Derek Mowlds, PM Group’s China Managing Director.
PM Group in China is working with local and multinational companies including AstraZeneca, Merck, Novartis, Abbott Nutrition, Givaudan and Wrigley amongst others.